Chronic lymphocytic leukemia
|
|
- Bruno Patterson
- 5 years ago
- Views:
Transcription
1 Chronic lymphocytic leukemia Tanya Siddiqi, MD Assistant Professor City of Hope National Medical Center Duarte, CA How the Experts Treat Hematologic Malignancies Las Vegas, NV 3/2017
2 Disclosures Speaker for Pharmacyclics/Janssen (ibrutinib) Speaker for Seattle Genetics (brentuximab vedotin) I will be mentioning off label use for some novel treatments currently being investigated
3 Objectives Epidemiology Diagnosis and workup Monoclonal B-lymphocytosis Prognostic markers Staging Treatment initiation guidelines Therapeutic options
4 Overview Chronic lymphocytic leukemia (CLL) is a low grade leukemic lymphocytic lymphoma; small lymphocytic lymphoma (SLL) is a nodal form of the same disease CLL/SLL is the most common hematological malignancy in the Western world; incidence is ~5/100,000 persons per year in the US; median age at diagnosis ~72 years Male predominance; higher in Caucasians Exact etiology is unknown; ~10% patients with a family history of some lymphoma Muller-Hermlink HK, et al. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours in Haematopoietic and Lymphoid Tissues. Lyon, France. IARC press, 2001:
5 Initial Presentation Clinical course is variable Many are asymptomatic at diagnosis Referred when white blood cell and/or lymphocyte counts are elevated on routine tests 10% have B symptoms Nabhan C et al. JAMA. 2014;312: Furman RR. Hematology Am Soc Hematol Educ Program. 2010:77-81.
6 Initial Workup H&P, performance status: note any B-symptoms CBC, differential, CMP, LDH, direct Coombs test Flow cytometry for diagnosis and to rule out masquerading lymphomas Peripheral blood monoclonal B lymphocytes 5 x 10 9 /L Immunophenotyping: k/l dim, CD5+, CD19+, CD20 dim, CD23+, CD10-, cyclin D1- FISH t(11;14) Imaging studies and bone marrow/ln biopsies are not routinely required NCCN Guidelines for Non-Hodgkin s Lymphomas Version
7 Monoclonal B-lymphocytosis (MBL) Presence of monoclonal lymphocytosis but with <5000 B-cells/uL in the peripheral blood and no accompanying lymphadenopathy or organomegaly by physical examination or radiographical imaging, cytopenias or disease-related symptoms is defined as MBL Incidence in the US is 3% Progression to CLL/SLL can 1-2% per year
8 Prognostic markers in CLL/SLL Cytogenetics/FISH: Del13q Trisomy 12 Del11q Del17p Del6q Mutations: TP53 mutations Notch1 mutations SF3B1 mutations IgVH mutation status ZAP70 CD38 Lymphocyte doubling time β2 microglobulin Rai/Binet stage
9 CLL Staging Rai stage Risk category Clinical features 0 Low Lymphocytosis alone 1 Intermediate Lymphadenopathy 2 Intermediate Hepato/splenomegaly 3 High Anemia (<11g/dl) 4 High Thrombocytopenia (<100,000/L) Binet stage A B C Clinical features HGB 10 g/dl, platelets 100/L, <3 areas of lymphadenopathy/ organomegaly* HGB 10 g/dl, platelets 100/L, 3 areas of lymphadenopathy/ organomegaly* Anemia (<10g/dl), thrombocytopenia (<100,000/L), or both *nodal areas: cervical [head and neck], axillary, inguinal (including femoral lymph nodes), spleen, liver
10 CLL Disease Progression Curve Adapted from:
11 MRD in CLL Retrospective study N = 255 CR after 1 st line chemoimmunotherapy Median followup = 73 months from disease evaluation Median treatment free durations: MRD neg CR 76 months MRD pos CR 40 months PR 11 months No response 11 months MRD negativity also affected OS significantly Pts from CLL8 and CLL10 trials N = 542 CR after 1 st line chemoimmunotherapy Median followup = 45.9 months PFS difference [p<0.001]: MRD neg CR 69.2 months MRD pos CR 40.4 months Also, PFS difference [p<0.008]: MRD neg PR 61.7 months MRD pos CR 40.4 months No PFS difference between MRD neg CR and MRD neg PR Santacruz R, et al. Haematologica 2014; 99 Kovacs G, et al. Blood 2014; ASH abstract
12 Course of CLL/SLL Remains incurable with current available therapies Therapies are associated with morbidity and mortality Current recommendation: watch and wait until patients develop active disease
13 Who needs treatment? International workshop on CLL (iwcll) guidelines for treatment initiation Hallek M, et al. Blood :
14 iwcll guidelines for treatment initiation progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia massive ( 6cm below left subcostal margin), progressive, or symptomatic splenomegaly massive ( 10cm in longest diameter), progressive, or symptomatic lymphadenopathy progressive lymphocytosis with an increase of >50% over a 2 month period or LDT of <6 months autoimmune hemolytic anemia and/or thrombocytopenia that is poorly responsive to corticosteroids or other standard therapy constitutional symptoms defined as 1 of the following: (i) unintentional weight loss of 10% within the previous 6months (ii) significant fatigue (ECOG PS 2;inability to work or perform usual activities) (iii) fevers >100.5F or 38C for 2 weeks without other evidence of infection (iv) night sweats for >1 month without evidence of infection
15 Who needs treatment and how to pick the right first line regimen? iwcll guidelines for treatment initiation Stage of disease Symptoms Fitness of patient Cytogenetic risk
16 Therapeutic options for CLL Watch and wait Radiation Immunotherapy Chemotherapy Combination chemoimmunotherapy Novel targeted therapies Cellular therapy Clinical trials
17 GCLLSG: frontline treatment (cont.) CLL11 study: Chlorambucil + obinutuzumab vs. Chlorambucil + Rituximab vs. chlorambucil alone Randomized, previously untreated, CLL patients with comorbidities N = 781 Median age = 73 years 3 arms of the study = G+Clb vs. R+Clb vs. Clb alone for 6 cycles Goede V, et al. NEJM 2014; 370:
18 Obinutuzumab + Clb: NEJM ;12:1101(cont.) 3 months after treatment, CRs were seen exclusively after antibody combinations compared with Clb alone Median PFS was 26.7 months (G-Clb) vs 11.1 months (Clb) [p<0.001] and 16.3 months (R-Clb) vs 11.1 months (Clb) [p<0.001] G-Clb improved OS compared to Clb (p=0.002) G-Clb improved PFS (p<0.001), CRs (20.7% vs 7%) and molecular responses compared to R-Clb
19 German CLL study group (GCLLSG): frontline treatment CLL4 study: FC vs. fludarabine alone CLL8 study: FCR vs. FC Subgroup with exceptionally good outcome has right age/fitness, mutated IGHV genes and no del17p/del11q (plateau after 4 yrs; MRD neg 6 yrs later) CLL10 study: FCR vs. BR Eichhorst BF, et al. Hematol J 2006; 107: Hallek M, et al. Lancet 2010; 376: Eichhorst B, et al. Blood 2014; 124: abs.19 Lancet Oncol 2016 Jul; epub 2016 May 20
20 FCR vs. BR: ASH 2014 abstract Phase 3 randomized trial, fit CLL patients with advanced stage disease, previously untreated, no 17p deletion Planned interim analysis N = 564; 6 cycles of either regimen FCR BR P-value ORR 97.8% 97.8% 1.0 CR 40.4% 31.5% [higher MRD negative CRs in FCR arm] Median PFS 53.7 months 43.2 months [better in <65 years old] OS at 3 years 90.6% 92.2% Severe neutropenia 87.7% 67.8% <0.001 Severe infections 39.8% 25.4% [especially in older pts]
21 ASH2016 MDACC experience with FCR N=289 [median age 59 yrs] Prospective analysis of pts getting frontline FCR Bone marrow biopsy after cycle 3 (n=239) and at end of treatment (n=231) ORR=96% 19% had MRD neg after cycle 3 and 51% at end of treatment patients with IGHV-M who achieved MRD-negativity after 3 courses had a particularly favorable outcome The best pre-treatment predictor of achieving MRD-negativity and subsequent longer PFS was IGHV-M Despite achieving MRD-negativity, many patients subsequently relapse; serial MRD monitoring in peripheral blood can herald relapse with a lead-time of approximately 2 years and potentially direct monitoring and/or early intervention strategies. Thompson et al. ASH 2016
22 Targeted therapies (small molecule inhibitors)
23 Monoclonal antibodies: update Anti-CD20 (dim expression on CLL/SLL cells typically) Obinutuzumab Ublituximab Anti-CD37 (expressed strongly on the surface of B-cells and transformed mature B-cell leukemia and lymphoma cells)
24 BTK inhibitors Ibrutinib ACP-196 (Acalabrutinib) CC-292 ONO-4059
25 Ibrutinib Ph1b/2 study of 85 CLL pts, mostly high risk ORR of 71% (2 CR, 34 PR) % PR-L At 26 months, estimated PFS was 75% and OS 83% Well tolerated Byrd JC, et al. N Engl J Med 2013; 369: 32-42
26 Ibrutinib: RESONATE trial Phase 3 trial of ibrutinib (420mg po daily) vs. ofatumumab in r/r CLL N = 391 ORR 42.6% (+20% PR-L) vs. 4.1% (p<0.001) Median PFS not reached (88% PFS at 6 months) vs. 8.1 months (p<0.001) At 12 months, OS 90% (ibru) vs. 81% (ofa) (p=0.005) Byrd JC, et al. N Engl J Med 2014; 371:
27 PCYC-1102/1103 Phase 2: 5 year update ASH2016 Phase 2 (PCYC-1102) N=132 Extension Study (PCYC-1103) Patients with CLL/SLL treated with oral, once-daily ibrutinib (420 or 840 mg/day) Treatment Naïve (TN) 65 years n=31 Relapsed/Refracto ry * (R/R) n=101 SD Long-Term Follow-Up 5-year update, O Brien et al. ASH 2016 * R/R includes patients with high-risk CLL/SLL, defined as progression of disease <24 months after initiation of a chemoimmunotherapy regimen or failure to respond
28 Ibrutinib Treatment Continued in 65% of TN and 30% of R/R Patients Disposition Median time on study, months (range) Duration of study treatment, n (%) 1 year >1 2 years >2 3 years >3 4 years 4 years TN (n=31) 62 (1 67) 5 (16%) 0 1 (3%) 1 (3%) 24 (77%) R/R (n=101) 49 (1 67) 24 (24%) 14 (14%) 9 (9%) 19 (19%) 35 (35%) Patients remaining on ibrutinib therapy, n (%) 20 (65%) 30 (30%) Primary reason for discontinuation, n (%) Progressive disease Adverse event Consent withdrawal Investigator decision Lost to follow-up 1 (3%) 6 (19%) 3 (10%) 0 1 (3%) 33 (33%) 21 (21%) 5 (5%) 11 (11%) 1 (1%) After ~5 years of follow-up, 65% of TN and 30% of R/R patients continue treatment on study 5-year update, O Brien et al. ASH 2016
29 Cumulative Frequency of Grade 3 Adverse Events Over 5-Year Follow-Up Non-hematologic 5% Hematologic Infectious R/R TN R/R TN R/R TN Grade 3 Grade 4 Grade 5 5-year update, O Brien et al. ASH 2016
30 Best Response 100% 80% 60% 40% 20% TN (n=31) R/R (n=101) Total (N=132) 87% 89% 89% 10% 14% 29% 76% 71% 55% CR PR PR-L 0% Median DOR, months (range) Median followup, months (range) 3% 3% 3% NR (0.0+ to 65.5+) 56.8 (0.0+ to 65.5+) NR (0.0+ to 65.5+) 62 (1 67) 49 (1+ 67) 56 (1+ 67) NR, not reached. 5-year update, O Brien et al. ASH 2016
31 Best Response in Patients With High-Risk Abnormalities 100% 80% 60% R/R del11q (n=35) 97% 9% R/R Unmutated IGHV (n=79) 90% R/R Complex Karyotype (n=41) 90% 9% 7% R/R del17p (n=34) 79% 6% CR PR PR-L 40% 86% 77% 76% 65% 20% 3% 4% 7% 9% 0% Median DOR, 38.7 (0.0+ to 65.3+) 53.2 (0.0+ to 65.5+) 38.7 (0.0+ to 65.5+) 30.6 (0.0+ to 65.3+) months (range) Median followup, months 55 (1+ 67) 49 (1+ 67) 55 (1 67) 47 (1 67) (range) NR, not reached. 5-year update, O Brien et al. ASH 2016
32 Survival Outcomes: Overall Population Progression-Free Survival Overall Survival Median PFS 5-year PFS TN (n=31) NR 92% R/R (n=101) 52 mo 43% Median OS 5-year OS TN (n=31) NR 92% R/R (n=101) NR 57% NR, not reached. 5-year update, O Brien et al. ASH 2016
33 Ibrutinib: RESONATE-2 trial Ph3, international, open label, randomized trial of ibrutinib vs. Clb in previously untreated older CLL/SLL patients N = 269 Median age = 73 years ORR 86% vs. 35% (p<0.001) Significant improvement in EFS, PFS and OS with single agent ibrutinib compared to Clb Burger JA, et al. N Engl J Med 2015 Dec 17;373(25):
34 RESONATE-2 update PFS was significantly improved for ibrutinib across high-risk subgroups, including del11q and unmutated IGHV gene OS analysis resulted in 2-yr survival rate estimates of 95% (ibr) vs. 84% (clb) ORR was 92% with ibr vs 36% with clb (P<0.0001); CR/CRi within the ibr arm improved from 11% at 18.4 mo to 18% with longer follow-up of 28.6-mo RESONATE-2 update, Barr et al.ash2016
35 RESONATE-2 update 1 patient on each arm developed Richter s transformation 4 patients had disease progression and discontinued ibr 41% switched from clb to ibr Major hemorrhage in 7% (ibr) within the first 2 yrs Atrial fibrillation in 10% (ibr) 79% pts remain on ibr with median treatment duration of 28.5 months RESONATE-2 update, Barr et al.ash2016
36 Ibrutinib: RESONATE-17 trial Ph2 trial of r/r CLL/SLL with del17p Ibrutinib 420mg po qd until PD or unacceptable toxicity N = 144 Median prior regimens = 2 (range 1-7) Median age = 64 yrs At median followup of 11.5 months, investigator-assessed ORR was 82.6% (including 17.4% PR-L); CR/CRi in 3 patients Median PFS and median DOR not reached; at 12 months, 79% alive and progression free (88% responders were progression free) At primary analysis, 101 patients continue ibrutinib (70%) PD in 20 (including Richter s transformation in 11) Most frequently reported Grade 3-4 AEs were neutropenia (14%), anemia (8%), pneumonia (8%), and hypertension (8%); 7 had major bleed (5%) mostly grade 3 O Brien S, et al. Blood 2014; ASH abstract
37 Ibrutinib: HELIOS trial Ph3 multicenter, randomized (1:1), double blind study Ibrutinib+BR vs. placebo+br (crossover to ibrutinib permitted) Del 17p pts excluded N=578 (289 each) Median f/u=17 months mpfs not reached vs months in placebo arm IRC assessed PFS at 18 mo was 79% vs. 24% Most common AEs were nausea and neutropenia Chanan-Khan A, et al. Lancet Oncol 2016 Feb; epub 2015 Dec5
38 ACP-196 (acalabrutinib) Ph1/2 multicenter study N = 61, r/r disease 100mg po BID dose in ph2 portion Median f/u = 14.3 months ORR 95% (PR=85%, PR+L=10%, SD=5%) For the 18 patients with del17p, the response rate was 100% (PR=72%, PR+L=28%) In the 4 patients with prior idelalisib therapy, the response rate also was 100% (PR=75%, PR+L=25%) No dose-limiting toxic effects in ph1 portion; most common adverse events were headache (43%), diarrhea (39%), and increased weight (26%); most AEs were Grade 2 ACP-196 is a highly potent and selective oral Btk inhibitor with a favorable safety profile; it is being studied in Ph3 trials Byrd J, et al. New Engl J Med 2016; 374: 323
39 PI3K delta inhibitors Idelalisib IPI-145 (Duvelisib) TGR1202
40 Idelalisib Ph 3 multicenter, double blind, RCT of R + idela (150mg po BID)/placebo in 220 CLL pts with significant comorbities ORR (all PRs) 81% vs. 13% (p<0.001) Median PFS not reached (idela arm) vs. 5.5 months (p<0.001) OS at 12 months 92% vs. 80% (p=0.02) SAEs in 40% (idela arm) vs. 35% (placebo arm) mainly pneumonia, fever, F+N in both; 4 idela pts with gr3-4 diarrhea, 2 with rash, 6 with transaminitis - manageable Furman RR, et al. N Engl J Med 2014; 370: 997
41 Idelalisib Idelalisib+ofa Ph2 frontline study; significantly higher toxicities compared to r/r setting; n=21 grade 3 toxicities 76% (transaminitis 57%, enterocolitis (14%), pneumonitis (10%); toxicities appear immunemediated 76% patients required steroids 5% required mycophenolate mofetil Lampson BL, et al. ASH 2015 abs
42 Duvelisib FCR+duvelisib Ph1b, frontline N=12 ORR=100% CR=33% MRD neg=89% Davids M, et al. ASH 2015 abs
43 TGR-1202 Oral agent Unique structure different from other PI3Kδ inhibitors Promising single agent activity and in combination with ublituximab Ph1b combination study in CLL/NHL No liver or colitis type toxicities Ph3 studies now starting TGR-1202 Idelalisib IPI-145 Type Pts (n) ORR (%) Median Prior Rx CLL/SLL 16 5/7 evaluable at high dose (71%) 3 (1 9) Lunning M, et al. ASH2015
44 BCL2 inhibitors ABT199 (venetoclax)
45 ABT199 ABT-199 alone ABT-199+R 1 st generation oral Bcl2 inhibitor ABT-263 had 35% RR in heavily pretreated CLL pts, but caused significant thrombocytopenia 2 nd generation oral inhibitor ABT-199 is highly selective for Bcl2 and TLS is primary toxicity better with gradual weekly dose increments Seymour JF et al. EHA abs. S702, Haematologica 2014; 99 (s1) Roberts AW, et al. EHA abs. S703, Haematologica 2014; 99 (s1)
46 ABT-199+R Ph1b trial r/r CLL/SLL N = 49, 20% with del17p Median age = 68 years Median prior regimens = 2 (1-5 range) Median followup 17.4 months ORR = 86% (53% MRD neg) - 20 (41%) CR/CRi (75% MRD neg), 1 (2%) npr and 21 (43%) PR, 4 SD, 2 PD; 1 died before assessment (fatal TLS) Median PFS and OS not reached (87% and 94% respectively at 12 months) Most common gr3 AEs were heme, F+N Ma S, et al. Blood 2015; ASH abstract
47 ABT-199 (venetoclax) ASH 2015: LBA of ABT199 in r/r CLL with del17p (Ph2) N = 107 Primary endpoint of IRC-assessed ORR was 79.4% including 7.5% CR/CRi and 2.8% npr, by IRC 18 pts (17% of whole cohort, 21% of responders) had no detectable MRD in the PB; 10 of these also tested in BM, 6 were MRD-negative Overall median DoR, PFS, and OS were not reached. The actuarial 12-month PFS and OS rates were 72.0% and 86.7%, respectively 37 pts discontinued treatment: 22 PD (9 Richter's transformation), 9 AE, 2 withdrew consent, and 1 with non-compliance; 3 proceeded to allo-sct (2 PR, 1 CR by IRC at time of transplant) 11 deaths ( 30 days from last dose): 7 PD, 4 AE (stroke, liver derangement, septic shock, and cardio-respiratory insufficiency) Stilgenbauer S, et al. Blood 2015, ASH abs.
48 Cellular therapy Allogeneic hematopoietic cell transplantation N=694 (retrospective) High risk disease 2 yr-nrm 28% 5 yr EFS 37% CAR-T cells Schetelig J, et al. ASH 2015 abs
49 CD19 specific CAR-T cells N = 14; median cell dose = 7.5x10^8 cells 4 CRs (29%), 4 (29%) PRs, ORR 57% CAR-T cells detectable 3 yrs later in some Ph2 randomized study ongoing to determine best cell dose Expected toxicities: B cell aplasia, delayed TLS and cytokine release syndrome Porter D, et al. Blood 2013; ASH abs Porter D, et al. Blood 2013; ASH abs. 873
50 CD19 specific CAR-T cells (cont.) CAR-T cell therapy may potentially be a good alternative to RIC allohct for very high risk patients Other targets being evaluated include CD20, CD23, ROR1 Mato A and Porter D. Blood 2015; 126: 478
51 ASH 2016 update (frontline therapies) Ibrutinib+FCR in young fit patients (Davids, et al) Ph2 N=35 Median age=55 yrs ORR 100% in 28 evaluable pts including 39% CR/Cri and 61% PR (all PR pts had residual nodes <2.5cm and 76% had MRD neg bone marrows) 11/26 (39%) evaluable pts (with bone marrow biopsies) in MRD neg CR CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine, Obinutuzumab and Venetoclax in TN or RR CLL: Interim Safety Results of a Ph2 Trial of the GCLLSG (Cramer et al) Debulking, induction and maintenance steps N=66 (35TN, 31RR) Median age 59 yrs
52 ASH 2016 update (frontline therapies) Phase Ib Study (GO28440) of Venetoclax with BR or Bendamustine/Obinutuzumab in TN/RR CLL (Stilgenbauer et al) Interim analysis N=55 (47 venbr, 8 venbg)
53 ASH 2016 update (frontline therapies) Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs PFS in High Risk CLL: Interim Results of Phase 3 CLL M1 study of GCLLSG (Fink et al) N=89 (60 len, 29 placebo) Median age=64 yrs Median of 10 prior lines of therapy Median f/u=17.7 months, median PFS was 14.6 months (placebo) vs. NR (len) More neutropenia with len (30.4% vs 3.4%) but not infections (50% vs 62.1%)
54 Conclusions Explosion of novel therapies for CLL in recent years, including monoclonal antibodies (like obinutuzumab), small molecule inhibitors of various kinases (like BTK and PI3K) and the antiapoptotic pathway (especially Bcl2), and CD19-specific CAR-T cells These novel, non-chemotherapeutic agents may do away with the need for standard chemoimmunotherapy in CLL, especially in older/unfit patients Combination studies underway
55 Standard of care algorithm (frontline): clinical trials if possible
56 Frontline CLL trials at City of Hope Phase 3 TGR1202+ublituximab vs. TGR1202 vs. ublituximab vs. Gazyva+chlorambucil [crossover allowed] Phase 2 ibrutinib+venetoclax
57 Relapsed/refractory CLL trials at COH Ph3 randomized trial of ACP-196 vs ibrutinib in del17p/del11q patients Ph1b/2 trial of TGR1202+ublituximab+ibrutinib Ph1 ibrutinib+cd37 monoclonal antibody Ph1 pembrolizumab+dinaciclib Coming soon: Ritonavir+metformin trial [COH], ibrutinib+venetoclax [with Stanford], CAR-T cell trial in B- cell lymphomas [COH]
58 Acknowledgements Dr. Stephen Rosen Dr. Stephen Forman Patients and their families/friends, nurses, colleagues at City of Hope National Medical Center
59 ?s
Chronic lymphocytic leukemia
Chronic lymphocytic leukemia How the Experts Treat Hematologic Malignancies Las Vegas, NV 3/2018 Tanya Siddiqi, MD Assistant Professor City of Hope National Medical Center Duarte, CA DISCLOSURES I am on
More informationHighlights in chronic lymphocytic leukemia
Congress Highlights CLL Highlights in chronic lymphocytic leukemia A. Janssens, MD, PhD 1 As new data on indolent non-hodgkin lymphoma (inhl) were not that compelling, only highlights on chronic lymphocytic
More informationUPDATES IN CHRONIC LYMPHOCYTIC LEUKEMIA TANYA SIDDIQI, MD
UPDATES IN CHRONIC LYMPHOCYTIC LEUKEMIA TANYA SIDDIQI, MD DISCLOSURE Speaker s bureau: Pharmacyclics, Janssen, Seattle Genetics, Astra Zeneca Consultant: Juno therapeutics, Astra Zeneca, BeiGene, Pharmacyclics
More informationBackground. Approved by FDA and EMEA for CLL and allows for treatment without chemotherapy in all lines of therapy
Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Abstract
More informationChronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD
Chronic Lymphocytic Leukemia (CLL): Refresher Course for Hematologists Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang-Mai University Outline
More informationIdelalisib in the Treatment of Chronic Lymphocytic Leukemia
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL
More informationManagement of 17p Deleted CLL Patients in the Era of Targeted Therapy
Management of 17p Deleted CLL Patients in the Era of Targeted Therapy Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November 11,
More informationChronic lymphocytic Leukemia
Chronic lymphocytic Leukemia after IwCLL, ICML and EHA 2017 Ann Janssens, MD, PhD Hematology, UZ Leuven Brussels, 14 september 2017 Front line treatment CLL Active or progressive disease No active or progressive
More informationReviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto)
CLL Updated March 2017 by Doreen Ezeife Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto) DISCLAIMER: The following
More informationManagement of CLL in the Targeted Therapy Era
Management of CLL in the Targeted Therapy Era Jennifer A. Woyach, MD The Ohio State University The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove
More informationRaising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division
Raising the Bar in CLL Michael E. Williams, MD, ScM Byrd S. Leavell Professor of Medicine Chief, Hematology/Oncology Division University of Virginia Cancer Center The Clinical Continuum of CLL Early asymptomatic
More informationMRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients
MRD Negativity as an Outcome in CLL: Ongoing Challenges with Del 17p Patients Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute Associate Professor Harvard Medical School November
More informationClinical Overview: MRD in CLL. Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel
Clinical Overview: MRD in CLL Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel m.ritgen@med2.uni-kiel.de Remission in CLL Clinical criteria (NCI->WHO) Lymphadenopathy Splenomegaly Hepatomegaly
More informationCLL & SLL: Current Management & Treatment. Dr. Peter Anglin
CLL & SLL: Current Management & Treatment Dr. Peter Anglin Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of blood cell B lymphocyte Lymphocytic Cancer of white blood
More informationAdvances in CLL 2016
Advances in CLL 2016 The Geoffrey P. Herzig Memorial Symposium, Louisville, KY Kanti R. Rai, MD Northwell-Hofstra School of Medicine Long Island Jewish Medical Center New Hyde Park, NY Disclosures Member
More informationCLL & SLL: Current Management & Treatment. Dr. Isabelle Bence-Bruckler
CLL & SLL: Current Management & Treatment Dr. Isabelle Bence-Bruckler Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of white blood cell B lymphocyte Lymphocytic Cancer
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationCLL what do I need to know as an Internist in Taimur Sher MD Associate Professor of Medicine Mayo Clinic
CLL what do I need to know as an Internist in 218 Taimur Sher MD Associate Professor of Medicine Mayo Clinic Case 1 7 y/o white male for yearly medical evaluation Doing well and healthy Past medical history
More informationBENDAMUSTINE + RITUXIMAB IN CLL
BENDAMUSTINE + RITUXIMAB IN CLL Barbara Eichhorst Bologna 13. November 2017 CONFLICT OF INTERESTS 1. Advisory Boards Janssen, Gilead, Roche, Abbvie, GSK 2. Honoraria Roche, GSK, Gilead, Janssen, Abbvie,
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationChronic Lymphocytic Leukemia. Paolo Ghia
Chronic Lymphocytic Leukemia Paolo Ghia Complex Karyotype: a novel predictive marker? Thompson PA et al. Cancer 2015 Complex karyotype superseded del(17p) Anderson MA et al. Blood 2017 Ibrutinib and Idela
More informationCLL: future therapies. Dr. Nathalie Johnson
CLL: future therapies Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck Outline Treatment of relapsed
More informationCLL: Future Therapies. Dr. Anca Prica
CLL: Future Therapies Dr. Anca Prica Treatment Options: Improved by Decade 1960 1970 1980 1990 2000 2017 5% CR 5% CR Chemo Alkylator chlorambucil or cyclophosphamide 25% CR Chemo Purine analogues Fludarabine
More informationFCR and BR: When to use, how to use?
FCR and BR: When to use, how to use? Mitchell R. Smith, M.D., Ph.D. Director of Lymphoid Malignancy Program Taussig Cancer Institute Cleveland Clinic, Cleveland, OH DEBATE ISSUE 2013: Which is the optimal
More informationCLL Ireland Information Day Presentation
CLL Ireland Information Day Presentation 5 May 2018 Professor Patrick Thornton Consultant Haematologist, Senior Lecturer RCSI, and Clinical Director Hermitage Medical Clinic Laboratory Chronic Lymphocytic
More informationChronic Lymphocytic Leukemia: State of the Art
14th Annual INDY Hematology Review March 2017 Chronic Lymphocytic Leukemia: State of the Art Adrian Wiestner, MD/PhD Bethesda, MD awiestner@hotmail.com Disclosures Grant/research support: Pharmacyclics
More informationChronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances
Chronic Lymphocytic Leukemia: Prognostic Factors, Supportive Care Issues and Therapeutic Advances 2017 Master Class Course John C. Byrd, MD D Warren Brown Chair of Leukemia Research Distinguished University
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationCHRONIC LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA Effective Date: January, 2017 The recommendations contained in this guideline are a consensus of the Alberta Provincial Hematology Tumour Team synthesis of currently accepted
More informationL approccio terapeu-co. Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro
L approccio terapeu-co Maria Rosaria Villa U.O.C. Ematologia P.O. Ascalesi ASLNA1Centro DISCLOSURE Nome: Maria Rosaria Cognome: Villa Impiego nell industria farmaceu7ca negli ul7mi 5 anni: NO Interssi
More informationCLL treatment algorithm and state of the art
CLL treatment algorithm and state of the art Davide Rossi, M.D., Ph.D. Hematology IOSI - Oncology Institute of Southern Switzerland IOR - Institute of Oncology Research Bellinzona - Switzerland CLL subgroups
More informationLEUCEMIA LINFATICA CRONICA
LEUCEMIA LINFATICA CRONICA Gianluca Gaidano SCDU Ematologia Dipartimento di Medicina Traslazionale Università del Piemonte Orientale Novara Outline CLL biology and pathogenesis Prognostication and prediction
More informationImproving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy
New Evidence reports on presentations given at ASH 2009 Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy From ASH 2009: Chronic Lymphocytic Leukemia
More informationWe Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT
We Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT Danielle M. Brander, MD Duke University Division of Hematologic Malignancies & Cell Therapy CLL & Indolent
More informationManagement of Chronic Lymphatic Leukemia Beyond conventional therapy
3 rd Young Hematologists Orientation Program SGPGI Lucknow August 18 th -19 th 218 Management of Chronic Lymphatic Leukemia Beyond conventional therapy Prof. Hari Menon. MD DM Department of Hemato-Oncology
More informationDuvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia
Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia Susan M. O Brien 1, Manish R. Patel 2,3, Brad Kahl 4, Steven Horwitz 5,
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationCHRONIC LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA Effective Date: June, 2018 Copyright (2018) Alberta Health Services This material is protected by Canadian and other international copyright laws. All rights reserved. This
More informationUpdate on Management of CLL. Presenter Disclosure Information. Chronic Lymphocytic Leukemia. Audience Response Question?
Welcome to Master Class for Oncologists New York, NY May 14, 2010 Session 5: 4:20 PM - 5:00 PM Update on Management of CLL John C. Byrd, MD D Warren Brown Professor of Leukemia Research Professor of Medicine
More informationBTK Inhibitors and BCL2 Antagonists
BTK Inhibitors and BCL2 Antagonists Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia and Indolent Lymphoma, Peter MacCallum Cancer
More informationDepartment of Medicine, Division of Hematology-Oncology, Weill Cornell Medical College, New York, NY 3
The Bruton s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) is Highly Active and Tolerable in Treatment Naïve (TN) Chronic Lymphocytic Leukemia (CLL) Patients: Interim Results of a Phase Ib/II Study
More informationLEUCEMIA LINFATICA CRONICA: TERAPIA DEL PAZIENTE IN RECIDIVA
CORSO TEORICO-PRATICO PER LA GESTIONE OTTIMALE DEI PAZIENTI AFFETTI DA LINFOMA MANTELLARE, LINFOMA FOLLICOLARE E LEUCEMIA LINFATICA CRONICA Torino, 21-23 Maggio 2018 LEUCEMIA LINFATICA CRONICA: TERAPIA
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationCLL Biology and Initial Management. Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology
CLL Biology and Initial Management Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology CLL- Epidemiology Most common adult leukemia 25-30% in western world Incidence in US 4.5
More informationAdvances in the treatment of Chronic Lymphocytic Leukemia
Advances in the treatment of Chronic Lymphocytic Leukemia Lab of B Cell Neoplasia - Division of Experimental Oncology Strategic Research Program on CLL Department of Onco-Hematology Università Vita-Salute
More informationManagement of Patients With Relapsed Chronic Lymphocytic Leukemia
Management of Patients With Relapsed Chronic Lymphocytic Leukemia Polina Shindiapina, MD, PhD, and Farrukh T. Awan, MD Abstract The management of chronic lymphocytic leukemia (CLL) has improved significantly
More informationAktuelle Therapiestandards und neue Entwicklungen bei der CLL Primärtherapie und Risikostratifikation
Aktuelle Therapiestandards und neue Entwicklungen bei der CLL Primärtherapie und Risikostratifikation Dr. med. Petra Langerbeins Universitätsklinik Köln Deutsche CLL Studiengruppe (DCLLSG) OFFENLEGUNG
More informationPost-ASH 2015 Chronic Lymphocytic Leukaemia. Anna Schuh Consultant Haematologist Oxford
Post-ASH 2015 Chronic Lymphocytic Leukaemia Anna Schuh Consultant Haematologist Oxford NEWS IN FRONT-LINE Consort Diagram CLL10 Study: FCR VS BR in Front-line 688 CLL patients screened centrally for: immunophenotype
More informationRole of Targeted Therapies in the Management of Chronic Lymphocytic Leukemia: From Clinical Data to Individualized Care Ryan Jacobs, MD
Role of Targeted Therapies in the Management of Chronic Lymphocytic Leukemia: From Clinical Data to Individualized Care Ryan Jacobs, MD Department of Hematology Levine Cancer Institute Carolinas Health
More informationDebate Examining Controversies in the Front-line Management of CLL: Chemo-immunotherapy vs. Continuous TKI Therapy
Debate Examining Controversies in the Front-line Management of CLL: Chemo-immunotherapy vs. Continuous TKI Therapy Steven Coutre, MD Stanford Cancer Institute William G. Wierda, MD, PhD The University
More informationChronic lymphocytic leukemia. E. Van Den Neste Cliniques UCL Saint-Luc, Brussels Post-ASH meeting January 2015
Chronic lymphocytic leukemia E. Van Den Neste Cliniques UCL Saint-Luc, Brussels Post-ASH meeting January 2015 Disclosures Travelling to ASH: Roche Consulting services: Janssen Questions in CLL: answers
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationChronic Lymphocytic Leukemia: State of the Art
14th Annual INDY Hematology Review March 2017 Chronic Lymphocytic Leukemia: State of the Art Adrian Wiestner, MD/PhD Bethesda, MD awiestner@hotmail.com Disclosures Grant/research support: Pharmacyclics
More informationGeorg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria
Chronic lymphocytic Leukemia Georg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria georg.hopfinger@wgkk.at CLL Diagnosis and Staging Risk Profile Assessment
More informationEmerging Treatments and Evolving Pathways for the Management of Chronic Lymphocytic Leukemia
Emerging Treatments and Evolving Pathways for the Management of Chronic Lymphocytic Leukemia This educational activity is supported by an educational grant from AbbVie Faculty Jennifer R Brown, MD PhD
More information15 th Annual Miami Cancer Meeting
15 th Annual Miami Cancer Meeting CLL and CML Mohamed A. Kharfan-Dabaja, MD, MBA, FACP Director, Blood and Marrow Transplantation and Cellular Therapies Mayo Clinic Jacksonville, FL 15 th Annual Miami
More informationNASDAQ: TGTX Jefferies Healthcare Conference June 2015
NASDAQ: TGTX Jefferies Healthcare Conference June 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationQuando e se è possibile e u/le o0enere una remissione completa
Quando e se è possibile e u/le o0enere una remissione completa 1) Clinical heterogeneity Disease characteris:cs Pa:ent characteris:cs 2) Modern chemoimmunotherpy approaches 3) New mechanism- based treatment
More informationCLL - venetoclax. Peter Hillmen St James s University Hospital Leeds 10 th May 2016
CLL - venetoclax Peter Hillmen peter.hillmen@nhs.net St James s University Hospital Leeds 10 th May 2016 Pathophysiology of CLL: Proliferation vs Apoptosis Proliferation Apoptosis Ki-67 Expression Bcl-2
More informationOutcomes of patients with CLL after discontinuing idelalisib
Outcomes of patients with CLL after discontinuing idelalisib Jacqueline C. Barrientos, Manmeen Kaur, Alexis Mark, Jaewon Chung, Nancy Driscoll, Alison Bender, Kanti R. Rai ASH Annual Meeting Abstracts
More informationDr Shankara Paneesha. ASH Highlights Department of Haematology & Stem cell Transplantation
ASH Highlights 2015 Themes of ASH 2015 Novel therapies - Myeloma AML Lymphoma Pd-L1 & PD-l inhibitors Emerging concepts in biology HIF-1a pathway Cautionary tales ASH Choosing Wisely list IFM/DFCI
More informationDefining the New Treatment Paradigm for Patients With Chronic Lymphocytic Leukemia
Defining the New Treatment Paradigm for Patients With Chronic Lymphocytic Leukemia Mollie Moran, CNP The James Cancer Hospital at The Ohio State University Jeffrey Jones, MD/MPH Ohio State University Comprehensive
More informationDFCR. Dept. of Medical Oncology, Dana-Farber Cancer Institute 2. Dept. of Medical Oncology, Beth Israel Deaconess Medical Center Boston, USA
A Phase IB/II Study of Duvelisib in Combination with FCR (DFCR) For Frontline Therapy for Younger CLL Patients DFCR Matthew S. Davids, MD, MMSc 1, David C. Fisher, MD 1, Svitlana Tyekucheva, PhD 1, Haesook
More informationThe International Peer-Reviewed Journal for The the International Practicing Oncologist/Hematologist. Other Advances in Leukemia/MDS ALL AML MDS
The Oncologist The International Peer-Reviewed Journal for The the International Practicing Oncologist/Hematologist Peer-Reviewed Journal for the Practicing Oncologist/Hematologist 20 th Anniversary Overview
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationDYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA
DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt,
More informationLeukemia. Roland B. Walter, MD PhD MS. Fred Hutchinson Cancer Research Center University of Washington
Leukemia Roland B. Walter, MD PhD MS Fred Hutchinson Cancer Research Center University of Washington Discussed Abstracts Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody
More informationASH up-date: Changing the Standard of Care for Patients with. (or: Who to treat with What When?)
ASH up-date: Changing the Standard of Care for Patients with B-cell Chronic Lymphocytic Leukaemia (or: Who to treat with What When?) Dr Anna Schuh, MD, PhD, MRCP, FRCPath Consultant and Senior Lecturer
More informationCLL: What s New from ASH
CLL: What s New from ASH John C. Byrd, MD D. Warren Brown Chair in Leukemia Research Professor of Medicine and Medicinal Chemistry Director, Division of Hematology The Ohio State University 2 Chronic Lymphocytic
More informationTolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced CLL and NHL
Tolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced and NHL Loretta Nastoupil, MD 1, Matthew A. Lunning, DO 2, Julie
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Apply recent clinical research findings with the newly FDA-approved combination of obinutuzumab and chlorambucil to the management and care of patients with previously
More information1. What to test. 2. When to test
Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Impact of CLL biological features on
More informationNASDAQ: TGTX. 33 rd Annual JP Morgan Healthcare Conference
NASDAQ: TGTX 33 rd Annual JP Morgan Healthcare Conference January 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities
More informationREAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA.
REAL LIFE AMBULATORIALE E STUDI CLINICI RANDOMIZZATI NELLA PROGRAMMAZIONE TERAPEUTICA DELLA LEUCEMIA LINFATICA CRONICA Roberta Murru Struttura Complessa Ematologia e Centro Trapianti Presidio Ospedaliero
More informationNew Treatments and Combinations for Relapsed Chronic Lymphocytic Leukemia (CLL) Susan O Brien UC Irvine Health
New Treatments and Combinations for Relapsed Chronic Lymphocytic Leukemia (CLL) Susan O Brien UC Irvine Health Five-Year Experience With Single-Agent Ibrutinib in Patients With Previously Untreated and
More informationMED B Form CLL. Johannes Schetelig. London 09/April/
www.ebmt.org MED B Form CLL Johannes Schetelig London 09/April/2013 Content Update on CLL (15 ) Experiment with mini MED B CLL Assessment of pre-treatment in CLL Cytogenetics in CLL What is the IGVH-Gene
More informationWhat s on the Horizon for Chronic Lymphocytic Leukemia?
What s on the Horizon for Chronic Lymphocytic Leukemia? Matthew S. Davids, MD, MMSc Associate Director Center for Chronic Lymphocytic Leukemia Assistant Professor of Medicine Harvard Medical School Dana
More informationState of the art: CAR-T cell therapy in lymphoma
State of the art: CAR-T cell therapy in lymphoma 14 th annual California Cancer Consortium conference Tanya Siddiqi, MD City of Hope Medical Center 8/11/18 Financial disclosures Consultant for Juno therapeutics
More informationWelcome & Introductions
Living with Chronic Lymphocytic Leukemia (CLL) Welcome & Introductions Dr. Brander s slides are available for download at www.lls.org/programs Wednesday, July 12, 2017 1 Living with Chronic Lymphocytic
More informationState of the Art Treatment for Relapsed Mantle Cell Lymphoma
Winship Cancer Institute of Emory University State of the Art Treatment for Relapsed Mantle Cell Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor, BMT Program Emory University- Winship Cancer Institute
More informationIdelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL
Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL Susan M O Brien, Andrew J Davies, Ian W Flinn, Ajay K Gopal, Thomas J Kipps, Gilles A Salles,
More informationInvestigation and Management of Chronic Lymphocytic Leukemia. James Johnston
Investigation and Management of Chronic Lymphocytic Leukemia James Johnston Site Specific Clinics CLL Clinic (787-4454) Erin Elphee BN James Johnston Rajat Kumar Matt Seftel (transplant) Myeloma Clinic
More informationIdelalisib given front-line for the treatment of CLL results in frequent and severe immune-mediated toxicities
Idelalisib given front-line for the treatment of CLL results in frequent and severe immune-mediated toxicities Benjamin L. Lampson, Tiago R. Matos, Siddha N. Kasar, Haesook Kim, Elizabeth A. Morgan, Laura
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia March 2, 2018
pan-canadian Oncology Drug Review Final Clinical Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia March 2, 2018 DISCLAIMER Not a Substitute for Professional Advice This report is
More informationTargeted Oncology Chronic Lymphocytic Leukemia Virtual Tumor Board
Targeted Oncology Chronic Lymphocytic Leukemia Virtual Tumor Board Segment 1 Segment Title: Case 1: An Elderly Patient With Newly Diagnosed High-Risk CLL Segment Description: William Wierda, MD, PhD, and
More informationBACKGROUND AND RATIONALE
SYNOPSIS Observational study on the use of B cell receptor kinase inhibitors and BCL2 antagonists prior to allogeneic hematopoietic stem cell transplantation for B cell malignancies: A joint project of
More informationLymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University
Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies
More informationCLL: State of the Art 2018
CLL: State of the Art 2018 Dr. Susan O Brien, MD Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center; Medical Director, Sue and Ralph Stern Center for Cancer Clinical Trials
More informationChronic Lymphocytic Leukemia: Current Concepts
Review Chronic Lymphocytic Leukemia: Current Concepts EUN-MI YU 1, ADAM KITTAI 2 and IMAD A. TABBARA 1 1 Department of Hematology/ Oncology, George Washington University, Washington, DC, U.S.A.; 2 Department
More informationSequencing of chronic lymphocytic leukemia therapies
CHRONIC LYMPHOCYTIC LEUKEMIA Sequencing of chronic lymphocytic leukemia therapies Jacqueline C. Barrientos CLL Research and Treatment Program, Department of Internal Medicine, Hofstra Northwell School
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationConstan'ne S Tam Victorian Comprehensive Cancer Center Melbourne, Australia
Constan'ne S Tam Victorian Comprehensive Cancer Center Melbourne, Australia BGB-3111: Kinase Selec.vity Rela.ve to Ibru.nib Equipotent against BTK compared to ibru.nib Higher selec.vity vs EGFR, ITK, JAK3,
More informationBrad S Kahl, MD. Tracks 1-21
I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib
More informationRisikoprofil-gesteuerte, individualisierte Therapiestrategien bei der CLL. Michael Hallek University of Cologne
Risikoprofil-gesteuerte, individualisierte Therapiestrategien bei der CLL Michael Hallek University of Cologne 100 90 80 70 60 Substantial progress in CLL therapy in one decade 50 40 complete remissions
More informationSecond Generation BTK Inhibitors Acalabrutinib (ACP-196) and Zanubrutinib (BGB-3111)
Second Generation BTK Inhibitors Acalabrutinib (ACP-196) and Zanubrutinib (BGB-3111) Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia
More informationMANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval
More informationFollicular Lymphoma New Agents. Idelalisib
Indolent Lymphoma Workshop Bologna 2017 Follicular Lymphoma New Agents Idelalisib Sven de Vos, MD, PhD Director, UCLA Lymphoma Program Los Angeles, CA Disclosures of Sven de Vos Company name Research support
More informationUNMET NEEDS OF PATIENTS WITH CLL/SLL AND FL. June 6, 2018
UNMET NEEDS OF PATIENTS WITH CLL/SLL AND FL June 6, 2018 0 PRESENTATION OVERVIEW IN CLL/SLL AND FL: Review patient heterogeneity and its connection to unmet needs Explore unmet needs within the CLL/SLL
More information